... Here we report a case of relapsed/refractory (R/R) ALK-positive LBCL with a prolonged complete response to single-agent nivolumab... Case Report: Here we report a case of relapsed/refractory (R/R) ALK-positive LBCL with a prolonged complete response to single-agent nivolumab... Conclusion: This is to our knowledge the first report of a complete response in a patient with primary refractory ALK-positive LBCL after treatment with nivolumab. Although recent reports showing low single-agent activity of checkpoint inhibitors in R/R DLBCL have been disappointing, patients with disease exhibiting exceptional response to immunotherapy are still seen and need to be further characterized. New cellular therapies may prove to be effective in these uncommon and aggressive lymphomas... READ ARTICLE
Clinical Lymphoma Myeloma and Leukemia DOI:10.1016/j.clml.2019.08.015
Authors: Jose D. Sandoval-Sus, Amanda Brahim, Alina Khan, Yehuda Deutsch, Barbara Raphael, Ali Ansari-Lari, Hugo F. Fernandez, Luis E. Raez
